İntrahepatik kolanjiokarsinomların lenf nodu diseksiyon sonuçları, cerrahi tedavi yöntemleri ve onkolojik sonuçları, tek merkez deneyimi

Year 2023, Volume: 22 Issue: 2, 85 - 89, 31.08.2023

Osman Aydın Volkan Öter Muhammed Kadri Çolakoğlu Yiğit Mehmet Özgün Erol Pişkin Erdal Birol Bostancı

https://doi.org/10.17941/agd.1336239

Abstract

Giriş ve Amaç: İntrahepatik kolanjiokarsinom, bir safra yolu kanseridir. İntrahepatik kolanjiokarsinom için mevcut tek küratif tedavi karaciğer rezeksiyonudur. Bu çalışmanın amacı, merkezimizde yapılan intrahepatik kolanjiokarsinomların lenf nodu diseksiyonu, cerrahi yönetimi ve nüks oranlarının sonuçlarını vermektir. Gereç ve Yöntem: Ocak 2019 – Ocak 2023 tarihleri arasında kliniğimizde intrahepatik kolanjiokarsinom tedavisi gören hastaların tıbbi kayıtları retrospektif olarak değerlendirildi. Bulgular: Kliniğimizde 24 hasta ameliyat edildi. Hastaların 12'si kadın, 12'si erkekti ve yaş ortalaması 52.75 ± 10.20 idi. Ortanca tümör boyutu 8.50 cm idi. Ameliyatta 12 hastaya sağ hepatektomi, 6 hastaya sol hepatektomi, 2 hastaya genişletilmiş sol hepatektomi, 2 hastaya santral hepatektomi ve 2 hastaya segment 4 artı 5 rezeksiyon uygulandı. Ortalama çıkarılan lenf nodu sayısı 9.95 ± 3.56 idi. 5 hastada malign lenf nodu görüldü. Postoperatif ortanca hastanede kalış süresi 13.50 gündü. Postoperatif ilk 3 ayda sadece 2 hastada mortalite gözlendi. Hastaların medyan genel sağkalımı 318.50 gündü. Sonuç: Çalışmamızın sonucunda preoperatif doğru evreleme ile seçilecek intrahepatik kolanjiokarsinom hastalarında, rezeke edilebilir tümörü olan hastaların komorbiditeleri ve durumları değerlendirilerek agresif cerrahi, cerrahi sırasında hepatoduodenal lenf nodlarının çıkarılması ve hastalarda karaciğer hacim genişletme işlemleri Remnant karaciğer hacim yetmezliği gelişebilecek hastalarda, küratif tek şans olan hastaların rezeksiyona zorlanmasının gerekli olduğu gösterilmiştir.

Keywords

İntrahepatik kolanjiokarsinoma, cerrahi, lenf nodu diseksiyonu

Lymph node dissection results, surgical management modalities and oncologic results of intrahepatic cholangiocarcinomas, single center experience

Abstract

Background and Aims: Intrahepatic cholangiocarcinoma is a cancer of the biliary tract. The only current curative treatment for intrahepatic cholangiocarcinoma is liver resection. The aim of this study is given the result of the lymph node dissection, surgical management and recurrens ratio of intrahepatic cholangiocarcinomas in our center. Material and Methods: The medical record of patients who were treated for intrahepatic cholangiocarcinoma in our clinic were retrospectively evaluated between January 2019 to January 2023. Results: Twenty four patients were operated in our clinic. Of the patients, 12 were female, 12 were male, and the mean age was 52.75 ± 10.20 years. The median tumor size was 8.50 cm. Twelve patients had right hepatectomy, 6 patients had left hepatectomy, 2 patients had extended left hepatectomy, 2 patients had central hepatectomy and 2 patients had segment 4 plus 5 resection in the operation. The mean number of lymph node removed was 9.95 ± 3.56. Malignant lymph node was seen in 5 patients. Postoperative median hospital stay was 13.50 days. Mortality was observed in only 2 patient in the first 3 months postoperatively. The median overall survival of the patients was 318.50 days. Conclusions: As a result of our study, in patients with intrahepatic cholangiocarcinoma, patients who will be selected with preoperative correct staging, aggressive surgery by evaluating the comorbidities and conditions of patients with resectable tumors, removal of hepatoduodenal lymph nodes during surgery, and liver volume expansion procedures in patients who may develop remnant liver volume failure, to force to resection, which is the only curative chance of patients is demonstrated that it is necessary.

Keywords

Intrahepatic cholangiocarcinoma, surgery, lymph node dissection

References

• 1- Lauterio A, De Carlis R, Centonze L, et al. Current surgical management of peri-hilar and intra-hepatic cholangiocarcinoma. Cancers (Basel). 2021;13:3657.
• 2- de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
• 3- National Cancer Institute. Definitions. Cancer Staging Manual, 8th ed.; National Cancer Institute AJCC: Bethseda, MA, USA, 2020.
• 4- DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-62.
• 5- Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 2015;121:3998-4006.
• 6- Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020;72:364-377.
• 7- Kim SH, Han DH, Choi GH, Choi JS, Kim KS. Oncologic impact of lymph node dissection for intrahepatic cholangiocarcinoma: a propensity score-matched study. J Gastrointest Surg 2019;23:538-44.
• 8- Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014;60:1268-89.
• 9- Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018;15:95-111.
• 10- Guglielmi A, Ruzzenente A, Campagnaro T, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009;33:1247-54.
• 11. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg 2014;149:432-8.
• 12. Luo X, Yuan L, Wang Y, Ge R, Sun Y, Wei G. Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study. J Gastrointest Surg 2014;18:562-72.
• 13. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis. JAMA Surg 2014;149:565-74.
• 14. Tang H, Lu W, Li B, Meng X, Dong J. Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore) 2016;95:e4621.
• 15- Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005;29:728-33.
• 16- Wang C, Ciren P, Danzeng A, et al. Anatomical resection improved the outcome of intrahepatic cholangiocarcinoma: A propensity score matching analysis of a retrospective cohort. J Oncol 2022;2022:4446243.
• 17- Rodrigues PM, Vogel A, Arrese M et al. Next-generation biomarkers for cholangiocarcinoma. Cancers (Basel) 2021;13:3222.
• 18- Qiu Y, He J, Chen X, et al. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. Clin Chim Acta 2018;480:186-92.
• 19- Li MX, Bi XY, Li ZY, et al. Impaction of surgical margin status on the survival outcome after surgical resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Surg Res 2016;203:163-73.